These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35342138)

  • 21. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan.
    Nakano Y; Kurano M; Morita Y; Shimura T; Yokoyama R; Qian C; Xia F; He F; Kishi Y; Okada J; Yoshikawa N; Nagura Y; Okazaki H; Moriya K; Seto Y; Kodama T; Yatomi Y
    Sci Rep; 2021 Feb; 11(1):2776. PubMed ID: 33531605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Posuwan N; Puenpa J; Sudhinaraset N; Chirathaworn C; Poovorawan Y
    Virol J; 2021 Mar; 18(1):52. PubMed ID: 33750394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance of four SARS-CoV-2 antibody assays in patients with COVID-19 or with bacterial and non-SARS-CoV-2 viral respiratory infections.
    Huber T; Steininger P; Irrgang P; Korn K; Tenbusch M; Diesch K; Achenbach S; Kremer AE; Werblow M; Vetter M; Bogdan C; Held J
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1983-1997. PubMed ID: 34109500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
    Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
    Front Immunol; 2021; 12():786554. PubMed ID: 35003104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection.
    Zervou FN; Louie P; Stachel A; Zacharioudakis IM; Ortiz-Mendez Y; Thomas K; Aguero-Rosenfeld ME
    J Med Virol; 2021 Sep; 93(9):5409-5415. PubMed ID: 33932299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients.
    Liu C; Yu X; Gao C; Zhang L; Zhai H; Hu Y; Liu E; Wang Q; Gao Y; Wei D; Zhang D; Han Y; Zhang X
    J Med Virol; 2021 Apr; 93(4):2227-2233. PubMed ID: 33135795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Closing the serological gap in the diagnostic testing for COVID-19: The value of anti-SARS-CoV-2 IgA antibodies.
    Infantino M; Manfredi M; Grossi V; Lari B; Fabbri S; Benucci M; Fortini A; Damiani A; Mobilia EM; Panciroli M; Pancani S; Pesce G
    J Med Virol; 2021 Mar; 93(3):1436-1442. PubMed ID: 32790181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of SARS-CoV-2-specific IgG detection with a rapid antibody kit for COVID-19 patients.
    Chong Y; Ikematsu H; Tani N; Arimizu Y; Watanabe H; Fukamachi Y; Yonekawa A; Iwasaka S; Nishida R; Eriguchi Y; Miyake N; Shimoda S; Nagasaki Y; Shimono N; Akashi K
    Influenza Other Respir Viruses; 2021 Jan; 15(1):13-18. PubMed ID: 32909661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
    Isho B; Abe KT; Zuo M; Jamal AJ; Rathod B; Wang JH; Li Z; Chao G; Rojas OL; Bang YM; Pu A; Christie-Holmes N; Gervais C; Ceccarelli D; Samavarchi-Tehrani P; Guvenc F; Budylowski P; Li A; Paterson A; Yue FY; Marin LM; Caldwell L; Wrana JL; Colwill K; Sicheri F; Mubareka S; Gray-Owen SD; Drews SJ; Siqueira WL; Barrios-Rodiles M; Ostrowski M; Rini JM; Durocher Y; McGeer AJ; Gommerman JL; Gingras AC
    Sci Immunol; 2020 Oct; 5(52):. PubMed ID: 33033173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of COVID-19 Severity and Immunoglobulin Presence Against Spike and Nucleocapsid Proteins in SARS-CoV-2.
    Takamatsu A; Oshiro S; Mizutani N; Tada T; Tabe Y; Miida T; Kirikae T; Tagashira Y
    Viral Immunol; 2022 Apr; 35(3):254-258. PubMed ID: 35290756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019.
    Kowitdamrong E; Puthanakit T; Jantarabenjakul W; Prompetchara E; Suchartlikitwong P; Putcharoen O; Hirankarn N
    PLoS One; 2020; 15(10):e0240502. PubMed ID: 33035234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Persistence of Anti-SARS-COV-2 IgG Antibodies.
    Yousefi Z; Taheri N; Dargahi M; Chaman R; Binesh E; Emamian MH; Jafari R
    Curr Microbiol; 2022 Feb; 79(4):96. PubMed ID: 35150319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [SARS-CoV2 anti-spike IgG response following COVID-19 mRNA vaccination (BNT162b2) in patients with hematological disorders].
    Hagihara M; Sugi T; Uchida T; Ohara S; Imai Y; Inoue M; Mitamura K
    Rinsho Ketsueki; 2022; 63(4):247-253. PubMed ID: 35491212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG antibody titers against SARS-CoV-2 nucleocapsid protein correlate with the severity of COVID-19 patients.
    Yang L; Xu Q; Yang B; Li J; Dong R; Da J; Ye Z; Xu Y; Zhou H; Zhang X; Liu L; Zha Y; Yu F
    BMC Microbiol; 2021 Dec; 21(1):351. PubMed ID: 34922455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analytical and clinical validation of an ELISA for specific SARS-CoV-2 IgG, IgA, and IgM antibodies.
    Tré-Hardy M; Wilmet A; Beukinga I; Favresse J; Dogné JM; Douxfils J; Blairon L
    J Med Virol; 2021 Feb; 93(2):803-811. PubMed ID: 32667733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.
    Bird PW; Badhwar V; Kennedy B; Ladani S; Tang JW
    J Med Virol; 2021 Jul; 93(7):4585-4591. PubMed ID: 33595119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.